The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Redefining early-onset cancer and risk of hereditary cancer predisposition.
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Genentech/Roche (I); Gyroscope (I); Neurogene (I); Optos (I); Outlook Therapeutics (I); Regeneron (I); Regenxbio (I)
 
Anna Maio
No Relationships to Disclose
 
Aliya Khurram
No Relationships to Disclose
 
Yelena Kemel
No Relationships to Disclose
 
Angelika Padunan
No Relationships to Disclose
 
Matilde Borio
No Relationships to Disclose
 
Margaret Sheehan
No Relationships to Disclose
 
Yonina R. Murciano-Goroff
Employment - Memorial Sloan-Kettering Cancer Center
Honoraria - Amgen; Virology Education
Research Funding - Andrew Sabin Family Foundation; Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation; Druckenmiller Center for Lung Cancer Research; Elucida Oncology (Inst); Endeavor BioMedicines (Inst); Hengrui Pharmaceutical (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Loxo/Lilly (Inst); Luzsana Biotechnology (Inst); National Cancer Institute; National Cancer Institute; Taiho Oncology (Inst); The Society of Memorial Sloan Kettering
Patents, Royalties, Other Intellectual Property - Rutgers University Press; Wolters Kluwer
Travel, Accommodations, Expenses - AstraZeneca
 
Michael Francis Walsh
No Relationships to Disclose
 
Marie Will
No Relationships to Disclose
 
Ying L Liu
Research Funding - AstraZeneca (Inst); Repare Therapeutics (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Maria Isabel Carlo
Honoraria - OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Alicia Latham
No Relationships to Disclose
 
Julia Lynne Glade Bender
Consulting or Advisory Role - Jazz Pharmaceuticals
Research Funding - Bayer (Inst); Eisai (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on a T lympboblastic lymphoma cell line, CUTLL1
Travel, Accommodations, Expenses - Amgen (Inst)
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; Eisai; Merck; Pfizer; SpringWorks Therapeutics
 
Andrea Cercek
Consulting or Advisory Role - Bayer; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen
Research Funding - GlaxoSmithKline; Rgenix (Inst); Seagen
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; AmMax Bio; Ayala Pharmaceuticals; Bayer; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; inhibrx; Kowa Pharmaceutical; Lilly; Medpacto; Servier
Research Funding - AmMax Bio (Inst); Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
David B. Solit
Stock and Other Ownership Interests - Fore Biotherapeutics; Pyramid Biosciences; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Fog Therapeutics; Fore Biotherapeutics; Pfizer; Scorpion Therapeutics; Vividion Therapeutics
 
Diana Mandelker
No Relationships to Disclose
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
Luis A. Diaz
Leadership - Epitope Diagnostics; Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Delfi Diagnostics; Epitope Diagnostics; Four Paws; Jounce Therapeutics; Kinnate Biopharma; Neophore; Personal Genome Diagnostics; Seer; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Four Paws; Kinnate Biopharma; Merck; Neophore; Personal Genome Diagnostics; Seer; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Other Relationship - Blackstone; Innovatus Capital Partners